|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Decibel Therapeutics, Inc. (DBTX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,900,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Decibel Therapeutics is a clinical-stage biotechnology company focused on discovering and developing transformative treatments for hearing and balance disorders. Co. is developing its primary gene therapy product candidate, DB-OTO, to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. In addition, Co. is advancing AAV.103 to restore hearing in individuals with mutations in the gap junction beta-2 gene and AAV.104 to restore hearing in individuals with mutations in the stereocilin gene. Co. is also developing DB-020 for the prevention of cisplatin-induced hearing loss, which it is evaluating in patients in a clinical trial.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Llc |
Director |
– • • |
2021-02-17 |
4 |
B |
$18.00 |
$29,999,988 |
I/I |
1,666,666 |
883,418 |
2.25 |
- |
|
| Orbimed Capital Llc |
Director |
– • • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,278,526 |
218,568 |
|
- |
|
| Glaxosmithkline Plc |
Director |
– • – |
2021-02-17 |
4 |
B |
$18.00 |
$2,700,000 |
I/I |
150,000 |
1,183,663 |
2.1 |
- |
|
| Glaxosmithkline Plc |
Director |
– • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,033,663 |
1,033,663 |
|
- |
|
| Casdin Partners Master Fund, L.p. |
10% Owner |
– – • |
2021-02-17 |
4 |
B |
$18.00 |
$10,350,000 |
I/I |
575,000 |
1,121,421 |
1.5 |
- |
|
| Casdin Partners Master Fund, L.p. |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
546,421 |
546,421 |
|
- |
|
| Exter Neil |
Director |
– • • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,092,516 |
3,139,685 |
|
- |
|
| Thompson Peter A |
Director |
– • • |
2021-02-17 |
4 |
B |
$18.00 |
$29,999,988 |
I/I |
1,666,666 |
883,418 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,278,526 |
218,568 |
|
- |
|
| Regeneron Pharmaceuticals Inc |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,097,314 |
2,097,314 |
|
- |
|
| Longevity Fund 2 Lp |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
79,143 |
79,143 |
|
- |
|
| Gv 2016, L.p. |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
321,978 |
321,978 |
|
- |
|
| Gv 2019, L.p. |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
819,631 |
819,631 |
|
- |
|
| Gv 2017, L.p. |
10% Owner |
– – • |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
494,649 |
494,649 |
|
- |
|
| Exter Neil |
Director |
– • • |
2021-02-11 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
47,169 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
47,169 |
|
- |
|
| Trask Anna |
See RemarksOfficer |
• – – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
18,188 |
|
- |
|
| Lee John Jui-Jen |
See RemarksOfficer |
• – – |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,144 |
|
- |
|
| Steven H. Holtzman Revocable Trust |
10% Owner |
– – • |
2021-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
67,786 |
|
- |
|
44 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
